Orion Oyj (OTCMKTS:ORINY) Sees Large Growth in Short Interest

Orion Oyj (OTCMKTS:ORINY) saw a large increase in short interest during the month of February. As of February 15th, there was short interest totalling 500 shares, an increase of 66.7% from the January 31st total of 300 shares. Based on an average daily volume of 1,000 shares, the short-interest ratio is presently 0.5 days.

Orion Oyj Stock Performance

OTCMKTS ORINY traded up $0.49 during trading hours on Tuesday, reaching $28.63. The stock had a trading volume of 946 shares, compared to its average volume of 3,498. Orion Oyj has a 52-week low of $17.50 and a 52-week high of $28.63. The stock has a fifty day moving average of $25.19 and a 200 day moving average of $25.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.41 and a current ratio of 2.42. The stock has a market cap of $8.08 billion, a P/E ratio of 22.72 and a beta of 0.25.

Orion Oyj (OTCMKTS:ORINY) last released its quarterly earnings data on Tuesday, February 25th. The company reported $0.28 EPS for the quarter. Orion Oyj had a net margin of 23.01% and a return on equity of 39.49%. The business had revenue of $463.41 million for the quarter. Sell-side analysts predict that Orion Oyj will post 1.18 earnings per share for the current year.

Analyst Ratings Changes

Separately, Nordea Equity Research cut Orion Oyj to a “hold” rating in a research report on Tuesday, February 4th.

Orion Oyj Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.